Sterile PBS or 0.9% saline for reconstitution/dilution. It is recommended to use the reconstituted/diluted product within one month.
Magrolimab/莫洛利单抗 细胞实验
Cell Line
Concentration
Treated Time
Description
References
TC32 cells
1–10 µg/mL
2–4 hours
Evaluate macrophage phagocytosis of ES cells, MAG significantly increased macrophage phagocytosis of ES cells
J Exp Clin Cancer Res. 2024 Jul 11;43(1):193
EWS502 cells
1–10 µg/mL
2–4 hours
Evaluate macrophage phagocytosis of ES cells, MAG significantly increased macrophage phagocytosis of ES cells
J Exp Clin Cancer Res. 2024 Jul 11;43(1):193
A673 cells
1–10 µg/mL
2–4 hours
Evaluate macrophage phagocytosis of ES cells, MAG significantly increased macrophage phagocytosis of ES cells
J Exp Clin Cancer Res. 2024 Jul 11;43(1):193
BT474
10 μg/mL
2 hours
To evaluate the phagocytic effect of Magrolimab combined with trastuzumab on HER2-positive breast cancer cells. Results showed that the combination treatment significantly increased macrophage-mediated phagocytosis.
Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2026849118
SKBR3
10 μg/mL
2 hours
To evaluate the phagocytic effect of Magrolimab combined with trastuzumab on HER2-positive breast cancer cells. Results showed that the combination treatment significantly increased macrophage-mediated phagocytosis.
Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2026849118
ES cells (A673, TC32, SKNMC)
1 µg/mL
2-4 hours
To evaluate the effect of MAG on macrophage phagocytosis of ES cells, results showed MAG significantly enhanced macrophage phagocytic activity against ES cells.
To evaluate the effect of Magrolimab (CD47-IgG s) in combination with rituximab on macrophage-mediated ADCP. Results showed that Magrolimab significantly enhanced the ADCP effect of rituximab on various lymphoma cell lines.
Front Immunol. 2022 Oct 27;13:929339
Magrolimab/莫洛利单抗 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
NSG mice
ES xenograft model
Intraperitoneal
150 µg/animal
Once per day for 12 days
Evaluate the effect of MAG on ES tumor growth and animal survival, MAG significantly reduced tumor burden and prolonged survival
J Exp Clin Cancer Res. 2024 Jul 11;43(1):193
NSG mice
HER2-positive breast cancer xenograft model
Intraperitoneal injection
250 μg every other day
Trastuzumab once a week, Magrolimab every other day for 7 weeks
To evaluate the antitumor effect of Magrolimab combined with trastuzumab on HER2-positive breast cancer xenograft models. Results showed that the combination treatment significantly inhibited tumor growth and maintained efficacy after treatment cessation.
Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2026849118
NSG mice
ES cell (A673-luc) or ES patient-derived xenograft (PDX) tumor model
Intraperitoneal
100 µg/animal
Once per day for 12 days
To evaluate the effect of MAG on ES tumor growth and metastasis in vivo, results showed MAG alone or in combination with CAR-NK and NKTR-255 significantly decreased primary tumor growth and lung metastasis, and extended animal survival.
J Immunother Cancer. 2024 Sep 12;12(9):e009726
NSG-SGM3 mice
Humanized mouse model
Intraperitoneal injection
6 mg/animal, 12-100 mg/animal
From day 4 to day 22 with dose escalation
Evaluation of CD47 blockade efficacy in the humanized Ewing sarcoma mouse model showed that magrolimab significantly reduced primary tumor growth, decreased lung metastasis, and prolonged animal survival.
搜索
